Kalaris Therapeutics, Inc. KLRS
1.35 USD -0.02 (-1.46%)
Regular-session close
1.35 0.00 0.00%
After hours · Nov 19, 4:00 PM ET
1.33 Day range 1.39
1.33 52-week range 11.88
- YTD
- -84.00%
- 1 year
- -79.79%
News
benzinga.com Citizens Maintains Market Outperform on Kalaris Therapeutics, Lowers Price Target to $20 Citizens analyst Jonathan Wolleben maintains Kalaris Therapeutics (NASDAQ:KLRS) with a Market Outperform and lowers the price target from $25 to $20.
benzinga.com Kalaris Therapeutics Q3 EPS $(0.46) Beats $(0.51) Estimate Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.51) by 9.8 percent. This is a 28.13 percent increase over losses of…
globenewswire.com Kalaris Reports Third Quarter 2026 Financial Results and Provides Business Update Preliminary data from the ongoing Phase 1b/2 study of TH103 in nAMD is now expected in 2H 2027 Recently completed technology transfer from pilot to commercial-scale manufacturer with test batches…
benzinga.com Alpha Buying: 3 Beaten-Down Biotech Stocks Backed by a Specialist Investor There are parts of the stock market where I am comfortable doing the research myself.Give me a community bank’s balance sheet, loan portfolio, and deposit information, and I can usually figure out…
defenseworld.net Kalaris Therapeutics Inc. (NASDAQ:KLRS) Stock Has Average Price Target of $18.75 Kalaris Therapeutics Inc. (NASDAQ: KLRS - Get Free Report) has been given an average recommendation of "Moderate Buy" by the seven brokerages that are covering the stock, Marketbeat.com reports. One…
globenewswire.com Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference BERKELEY HEIGHTS, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and…
globenewswire.com Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates Patient dosing is ongoing in the Phase 1b/2 study of TH103; preliminary data anticipated in 1H 2027 Potential Phase 3 clinical trials remain on track for initiation by year-end 2027 $93.5 million in…
defenseworld.net Kalaris Therapeutics (NASDAQ:KLRS) Shares Up 15.4% – Here’s What Happened Kalaris Therapeutics Inc. (NASDAQ: KLRS - Get Free Report)'s stock price rose 15.4% during mid-day trading on Monday. The company traded as high as $4.09 and last traded at $4.05. Approximately…
globenewswire.com KLRS: Abbott Cooper PLLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. (Formerly Allovir, Inc.) Stockholders Abbott Cooper PLLC is investigating fiduciary duty claims for Kalaris Therapeutics (formerly AlloVir) holders who owned shares before November 7, 2024.
globenewswire.com Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer Strategic finance leader with over 20+ years of experience in the biotechnology space CFO hire bolsters Kalaris' leadership team and supports continued growth of the company as it enrolls its Phase…
globenewswire.com Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts Data from the expanded cohorts reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreatment findings observed in the original cohorts
globenewswire.com Kalaris Appoints Laurie Keating to Board of Directors Highly experienced biotechnology executive and board member will assist Kalaris in achieving its next phase of growth Highly experienced biotechnology executive and board member will assist Kalaris…
globenewswire.com Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling BERKELEY HEIGHTS, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and…
globenewswire.com Kalaris to Present at Clinical Trials at the Summit 2026 BERKELEY HEIGHTS, N.J., June 12, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and…
globenewswire.com Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates Patient screening now underway in the Phase 1b/2 study with the latest drug product batch on track to be available to support upcoming dosing; preliminary data anticipated in 1H 2027 Planned Phase 3…
globenewswire.com Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates Positive initial data reported from Phase 1a Single Ascending Dose study in nAMD in December 2025; preliminary data from ongoing Phase 1b/2 study expected in 1H 2027
defenseworld.net Kalaris Therapeutics (NASDAQ:KLRS) Director Srinivas Akkaraju Buys 479,847 Shares of Stock Kalaris Therapeutics Inc. (NASDAQ: KLRS - Get Free Report) Director Srinivas Akkaraju purchased 479,847 shares of the business's stock in a transaction on Thursday, December 18th. The shares were…
seekingalpha.com Kalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 Catalysts Kalaris Therapeutics offers a differentiated approach to neovascular AMD with its lead candidate TH103, leveraging unique molecular engineering for improved efficacy and durability. KLRS's Phase 1a…
seekingalpha.com Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth Kalaris Therapeutics, Inc. raised $50M post-positive TH103 trial data, strengthening its cash position to fund TH103 clinical development. KLRS reported improved Q3 '25 results, with a net loss of…
globenewswire.com Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and…
globenewswire.com Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a single injection
newsfilecorp.com Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference Berkeley Heights, New Jersey--(Newsfile Corp. - November 24, 2025) - Kalaris Therapeutics, Inc. (Nasdaq: KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and…
globenewswire.com Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates Phase 1a Single Ascending Dose trial remains on track for initial clinical data to be reported by year end 2025 Phase 1b/2 Multiple Ascending Dose trial currently enrolling, intended to inform dose…
